Failure To Thrive: Endocrine Causes

Yesterday I wrote about the clinical entity failure to thrive (FTT).  This morning I realized that I had not really addressed the question of endocrine gland disorders that can be associated with FTT.  Probably, the reason I did not mention endocrine disorders was that they do not often cause FTT and if they do, the signs and symptoms usually make it easy to make a diagnosis.

As I discussed in the previous entry, the key feature in all patients with FTT is poor weight gain, with or without short stature.  With only a few exceptions, endocrine disorders that cause short stature are rarely associated with poor weight gain.  For example, patients with either growth hormone deficiency, hypothyroidism or Cushing’s disease (glucocorticoid excess) typically present with short stature, but are generally overweight for height.  The endocrine conditions that typically present with poor weight gain (with or without short stature include type 1 diabetes mellitus, adrenal insufficiency (i.e., Addison’s disease), and conditions associated with hypercalcemia such as hyperparathyroidism.  Usually, the signs and symptoms for these disorders are such that very little detective work is needed to figure out what the problem is.  The one exception might be adrenal insufficiency; I have been amazed at how often that diagnosis is delayed for a long time if the patient is being followed by a primary care doctor, despite many clues from the medical history and physical examination.  I suspect the main difficulty in diagnosing adrenal insufficiency, is that the various disorders that cause adrenal insufficiency are rare and many physicians (not pediatric endocrinologists) have little or no experience in dealing with the problem.  Be warned.

A Medical Whodunnit: 16 Month Old Female with Failure to Thrive

A couple of weeks ago I received a telephone call from SS, one of my daughter’s close friends from college.  SS, who lives in New York City, called my daughter, who lives in California, because she was concerned about her younger sister’s (RS) daughter, KS .  RS had been worried about her daughter’s growth.  RS told her sister SS about the problem and SS promptly called my daughter; I suspect SS called my daughter because the daughter of a pediatrician would be expected to know almost as much as a pediatrician.  Right?  Anyway, my daughter called me and I was warned to be expecting a phone call from SS, which I got the next day.  SS wanted to know if I would be willing to talk with her sister.  Of course I agreed and talked with RS the next day.  I learned that KS was 16 months old and had  been  diagnosed with failure to thrive (FTT).  RS wanted to know what FTT was and what I thought should be done.  The situation was a bit complicated because RS lives in the Netherlands and was just visiting the U.S.  The family (RS, her husband, and 2 daughters, MS, age 4 years, and KS) has health insurance in the Netherlands but no coverage in the U.S.  The diagnosis of FTT had been made by a pediatrician in New York who recommended that a large number of laboratory studies be carried out as soon as possible.  One question RS had for me was whether the tests needed to be done immediately or could wait until the family returned to the Netherlands in about 2 weeks; the pediatrician estimated that the tests would cost about $5000-$10,000 (blood work, x-rays, and MRI, etc).

The Medical History

I first told RS that I would be happy to discuss things with her but that she needed to understand that it is always risky to get “curbside” consultations and that without actually seeing a patient, it is difficult for a physician to give a well-reasoned opinion,  and that my advice should be considered in that light.  KS was born full-term after an uneventful pregnancy.  There were no problems at birth and initially the infant seemed to do very well, following the 50% for height and weight until about age 6 months.  RS and her husband were of average height and their older daughter, MS was at about 60% for height and weight.  The infant was being exclusively breast-fed. After age 6 months, the infant slowed her growth rate, falling to about 40% for height and 5% for weight by age 1 year; at age 15 months, the height was still at about 40% but the weight percentile fell further, to about 2%.  At no time did the infant show actual weight loss.  KS seemed to be feeding well and was a happy baby although her development seemed to be a bit slower that that of her older sister; KS was babbling but still not walking.

The New York pediatrician who  saw KS  made the diagnosis of FTT based on the infant’s weight and the history of slow weight gain.  The pediatrician felt the physical examination was normal except for the weight and perhaps, slightly delayed motor development, and slightly decreased muscle tone.  As discussed above, the pediatrician recommended a series of studies but felt they could be delayed a few weeks (until the family returned to the Netherlands.  The pediatrician did order a complete blood count and basic blood chemistry tests (electrolytes, serum CO2, BUN, etc.) all of which showed normal results.  Hence, no anemia, and no evidence of kidney disease or metabolic disease associated with acidosis.

What is FTT, how is it diagnosed, and how is it treated?

The best definition I have yet seen of FTT was written by Cindy Christian and Nathan Blum in the textbook, Nelson Essentials of Pediatrics, 5th Edition (2006), Chapter 21, (Failure to thrive).  The authors wrote the following: “Failure to thrive (FTT) is a term given to malnourished infants and young children who fail to meet expected standards of growth.”  The authors went on to say that that the term FTT most often describes malnutrition related to environmental or psychosocial causes but that most children with FTT also have organic contributors.  The list of possible organic contributors is a long one and includes most every body system (e.g., genetic/congenital/anatomic, gastrointestinal, metabolic,  neurologic, renal, and hematologic disorders, as well as infections.  Thus, FTT is not really a specific diagnosis of anything but rather, a descriptor of certain signs and symptoms with poor weight gain always the “centerpiece.”  It’s sort of like a diagnosis of “limp,” which could be caused by anything from a rock in one’s shoe, to a serious bone or joint disease.  Regardless, once a paient is diagnosed with FTT,  every effort must be made to determine a specific etiologic diagnosis so that proper treatment, if any can be given in timely fashion.

How to sort through the myriad of diagnostic possibilities?

Once a diagnosis of FTT is made, the next step is for some knowledgeable health professional (e.g., nurse practitioner, pediatrician, pediatric endocrinologist) to get a detailed medical history.  The history should include as much information as possible about previous height and weight measurements and  laboratory test results.  In addition, the history should include detailed information about the infant’s feeding history and details about the family social history in an effort to uncover any potential environmental/psychosocial factors.  Next, a comprehensive physical examination should be performed that includes a developmental assessment. Well done medical histories and physical examinations are always “just what the doctor ordered” in any patient encounter, and in patients with FTT,  they are critically important.

The next step: developing a differential diagnosis

Armed with information from the medical history and physical examination, one can begin to develop a plan of action.  I usually start by asking myself 3 questions.  The first is whether, based on all the information available, I am reasonably confident the patient is normal and that the “poor” weight gain is/was a variant of normal and that no studies or treatment is needed.  Being reasonably confident is not the same thing as being 100% confident, and generally, such a patient should be seen for a follow-up clinic visit in the next 1-2 months.  The second question is whether I am reasonably confident the patient has a specific medical disorder that can explain the poor weight gain.  For example, if the history and physical examination strongly suggest a gastrointestinal basis for the poor weight gain, such as celiac disease, the next steps in the evaluation process are straightforward.  The third question is the most difficult one to deal with and is whether I am unable to decide whether the patient likely  is either normal or has some (as yet unknown) environmental/psychosocial and/or organic process to explain the poor weight gain.  Unfortunately, in my experience, even after a detailed medical history and physical examination, the answer to this question is often “yes,” necessitating considerable detective work.

Is the FTT merely a variant of normal growth?

It should be obvious that to determine if the FTT is not really FTT but only a normal growth variant, requires an understanding of normal growth.  I have discussed this subject in some detail in earlier entries but I will review things a bit for those of you who do not wish to hunt down the appropriate entries (I can’t even remember which ones, but they can be found by checking out entries in the growth disorders category.   Principle #1: children generally follow both weight and height growth channels very closely; if a child is at 50% for height at age 2 years, he or she is very likely to still be at that percentile at age 8 or 9 years of age.  Many normal children do not have height and height at the same percentile; it can be perfectly normal to be at 50% for height and 10% for weight and vice versa (but less desirable for a number of reasons that we will not discuss here).    There are 2 important exceptions to this principle; first, during infancy, children often do not stay in their height and weight channels.  Infants who are genetically programmed to be bigger than their height percentile at birth would suggest (to be precise, in children we pediatricians and pediatric endocrinologists, generally carry out length rather than height measurements up until age 2-3 years of age), show acceleration in both height and weight from the beginning, reaching the growth channel they will follow by about 1 year of age; premies often take somewhat longer.  For infants who are programmed to follow lower height and or weight channels than their height and or weight at birth, first follow the birth channels for about 6 months and then, gradually slow their growth rates- we call it “lag-down,” until about 18-20 months of age, at which point they track “like glue.”  The second exception to principle 1 is puberty.  All bets are off as to the growth rate (both height and weight) at puberty.  Children who are “destined” to end up at lower or higher height and or weight percentiles as adults than they followed during childhood, will generally fulfill their destinies.  Remember the following: Scottie dogs generally have Scottie dogs and Great Danes generally have Great Danes.  That saying is actually principle #2.

Back to KS

Remember KS, the 16 month old we were discussing?  Her growth pattern could be merely normal lag-down but I doubt it, since lag-down usually affects both height and weight.  Earlier, I didn’t mention that at the time of the visit to the pediatrician, RS was concerned that perhaps, KS was not getting adequate calories from the breast feeding alone.  KS decided to taper off the breast feeds and add table foods.  I got a follow-up from KS just the other day.  The family returned to the Netherlands, went to the clinic where the diagnosis of FTT was confirmed by a nurse practitioner, and an appointment was set up with a pediatrician; in the Netherlands, the primary care providers are often nurse practitioners.  But, RS told me that since decreasing the breast feeding and adding table foods ad lib, KS had been gaining weight like crazy and had progressed substantially with her development. So, in this instance it looks like the problem was inadequate calories and maybe a bit of vitamin D deficiency?  I am just speculating about the vitamin D deficiency but given that KS had not received any vitamin D supplementation and had been exclusively breast-fed, that’s a good possibility- vitamin D deficiency could explain the poor muscle tone and slow development.  The primary health care provider felt the problem was likely a nutritional one because of the much lower weight than height percentile and was betting on celiac disease or something like that (a reasonable hypothesis).  Anyway, we will need to wait until RS gives me another follow-up to find out if the problem in this case was more or less an environmental/psychosocial one rather than a systemic disorder.  I promise to let you know.  Finally, please do not infer from my entry that I am not a fan of breast feeding.  I think breast feeding is the way to go but that occasionally, problems do arise.  That’s why infants and children need regular check-ups by health care professionals who know all about monitoring growth (and breast feeding).  I suspect that for KS, part of the problem was related to the discontinuity in medical care because of the family travels between the U.S. and the Netherlands.  I am hoping things will turn out well.


Who Invented Tanner Sexual Staging?

Every pediatric endocrinologist knows what “Tanner staging” is and how to do it but I am amazed that many of my younger colleagues do not know who or what the word “Tanner” stands for.  In fact, Tanner staging is named after James Mourilyan Tanner, a distinguished English pediatrician who died on August 11, 2010 at the ripe old age of 90 years.  I had the honor and pleasure of having knowing Dr. Tanner whose contributions to pediatric endocrinology were enormous.  Tanner staging is a method developed by Dr. Tanner to describe in a series of steps, the progression of  sexual maturation in males and females from pre-pubertal (Tanner stage 1), to full adult sexual maturation (Tanner stage 5).  Thus, Dr. Tanner developed a method to grade the level of sexual maturation for breasts in girls, pubic and axillary hair in boys and girls, and genitalia (testes, scrotum, and penis) in males on a scale of 1-5.  Of course, to develop such a scale, Dr. Tanner first had to study the course of adolescent sexual development in a large number of girls and boys.  Dr. Tanner did this as part of his work in overseeing a long-term study of malnutrition in a large group of British children living in an orphanage in Harpenden England.  Not only did his work result in a method for characterizing a child’s level of sexual maturation, his work also led to the development of modern-day growth charts, so indispensable to growth assessment.

So, when you see a clinic note on a 10 year old girl in which the physician has written  “breast development was early T2 while pubic hair was T 3″ you can be sure every pediatric endocrinologist (and pediatrician) knows just what that patient’s pubertal status is.  None of this would have been possible without Dr Tanner’s meticulous data collection month after month and year after year in the Harpenden orphans.

Dr. Tanner was one of the first pediatric endocrinologists to use human growth hormone and I remember well a lecture he gave many years ago, long before recombinant DNA-derived growth hormone was available.  He lamented just how difficult it was to be certain that a patient did or did not have growth hormone deficiency; at the time, he estimated that even in “classic” cases, we over-diagnosed growth hormone deficiency about 30-40% of the time.  Personally, I don’t think we do even that well these days despite all the fancy new growth factor tests (e.g, IGF-1, IGFBP3)!

I also remember how he used to talk about the importance of careful measurements.  He lectured and wrote extensively on the proper way to measure children.  Along with another Englishman, Reginald Whitehouse, he promoted the use of stadiometers for quantifying height in children.(a stadiometer is a fancy yardstick, perhaps more properly called a meterstick, with a counterweighted head board and a counter for direct reading of the height.  A well-made stadiometer is expensive, but essential if one is to obtain reliable height measurements).

Anyway, for you younger pediatric endocrinologists out there, next time you carry out a physical examination in a child or adolescent and you do Tanner staging (which of course is a routine part of most  every physical examination performed by a pediatric endocrinologist) , remember who to thank for the sexual staging system.

Treating Children With Growth Hormone: Moral, Ethical, And Other Considerations

I want to call your attention to two recent articles in the New York Times that might just be of interest to you if you are a physician who cares for short children, if you are a parent of a short child or if you are short or just want to be taller.  Both articles were written by Jane E. Brody.  The first appeared in the Science Times section of the newspaper, Tuesday May 10, 2010 and was entitled “A Plus Side for Human Growth Hormone.”  As an aside, that section of the newspaper had several other very interesting articles including one on mammoth hemoglobin (here I don’t mean big hemoglobin but hemoglobin in prehistoric animals) and another on efforts to teach physicians about health care costs.  The other article was published Tuesday May 11, 2010 and was entitled “Short?  No Worries: Just Ask this Texan.

The first article is an excellent review on the current status of growth hormone therapy in children.  The newspaper article was based on a medical article published in April 2010 by Judith L Ross in the medical journal Pediatrics.  The newspaper article more or less summarizes the medical journal article and, in my opinion, provides an excellent and concise overview of the current status of growth hormone use in short children.  Ms. Brody and Dr. Ross  both danced around the somewhat contentious issue of using growth hormone injections to make normal but short children taller but who is to blame them?

The second article is basically a summary of a recently published book by John Schwartz entitled “Short: Walking tall When You’re Not tall at All.”  The book was published by Roaring Brook Press and, according to Ms. Brody, was written primarily for short teenagers.  I have not read the book yet but I will.  Based on the newspaper article, I think the book (or the newspaper article if you have lots of things “on your plate” at the moment) would be worthwhile reading not only for short teens but also their parents, friends, and physicians.

The Issues

In 1985, The U.S. Food and Drug Administration (FDA) approved the use of biosynthetically derived human growth hormone for children with growth hormone deficiency.  Since then, use of growth hormone has been a major growth industry; world-wide, annual sales of growth hormone are well into the billions of dollars.  The uses for growth hormone, legal and illegal, have expanded dramatically.  At present, only a small percentage of people taking growth hormone injections actually have growth hormone deficiency, as originally defined- some physicians and many pharmaceutical companies believe that growth hormone testing fails to identify many people (children and adults) who would benefit from treatment with the hormone.  I do not want to get into the issues here except to say that the question of whether to treat a person with growth hormone has become a very complicated one, with moral, ethical, and economic factors to consider.

There is no question that most short children who have no demonstrable medical condition responsible for the short stature can be made taller by several inches over their genetic potential (whatever that means these days) if they take enough growth hormone for long enough before their bone growth centers close.  The questions are whether the potential adult height benefit, whatever that might or might not be is worth it with respect to costs and complication risks.  I believe that reading both of the Jane Brody newspaper articles will give you a pretty good foundation for understanding the issues.  I’m not picking sides (at least in this entry) but one important consideration not really addressed in the articles is that whenever an insured patient is treated for whatever and the insurer “covers” the costs, all people covered by that insurer share in the costs.  Is it “fair” to make many people pay to enable a person to gain a few inches in height when the person does not have an demonstrable medical condition responsible for the short stature?   In my view, that’s an interesting question.  We cannot expect companies who sell growth hormone to give us an unbiased answer to the question.  Likewise, we cannot expect a physician who  benefits financially from a relationship with the company, to give an unbiased answer to the question.  Very interesting stuff.  I think I should have taken more philosophy courses in college rather than focusing on pre-med ones. How was I to know?

I’m Still Alive

I knew it had been a while since I last posted an entry, but I was astonished that it had been 2 months.  I apologize for my lazy behavior.  My only real excuse is that I have been following the often painful health care reform news and wanted to wait to write anything about it until there was (or maybe was not) an actual bill to discuss.  I’m still waiting.  But, I do want to mention 2 recent articles of interest.  The first was a nice discussion about hair loss in women.  The article entitled “When Hair Loss Strikes, A Doctor Is a Girl’s Best Friend,” and written by Lesley Alderman appeared in the New York Times on Saturday January 16, 2010.  It is a nice summary of the major causes and treatments for female hair loss, some of which are endocrine.

I would only add to the discussion that in some instances, hair loss is on an auto-immune basis (called alopecia areata if the hair loss is spotty or alopecia totalis if the loss is big time) and is strongly associated with certain other auto-immune disorders, particularly chronic lymphocytic thyroiditis (aka Hashimoto’s thyroiditis) and adrenal insufficiency.  If the hair loss is considerable and sustained over weeks-to-months, I would strongly recommend a visit to a dermatologist before embarking on potential therapeutic misadventures.

The second article which appeared in the New York Times Magazine on Sunday January 17, 2010 was written by Tom Dunkel and was entitled “Vigor Quest.” The article was a very interesting and surprisingly balanced discussion of the attempts by what appears to be an increasing number of people obsessed with prolonging their youth, or at least, their youthful performance in a variety of activities.  My interest in the subject is, of course, as an endocrinologist (not as an aging endocrinologist).  Much of the discussion in the article focused on testosterone and growth hormone, drugs about which much has been written in both the medical and non-medical literature.  The subject has been in the news quite a bit recently with the controversy surrounding use of these drugs in professional athletes.  There is no question that deficiency of either testosterone or growth hormone can impair athletic performance and affect overall vigor.  The still unanswered questions are whether taking one or both of these substances when there is no apparent deficiency can be helpful and if there are potentially serious side-effects.  It is good that the National Institutes of Health has embarked on a long-term (6 years) study of the potential mental and physical benefits of testosterone therapy in elderly men.  They should also consider a companion study of growth hormone.  I for one strongly recommend that until we have much more scientific information, use of these biological agents be limited to patients who have definite deficiencies and symptoms and signs to match the laboratory findings.  But, I just wonder how fast I could swim if………?

Medical Whodunnit: 7 Year Old Male With Rapid Growth

I haven’t posted a medical whodunnit for a while and I’ve got a good one (at least I think it’s a good case).  The patient is a 7 year old male whose mother told a friend that her son, Jimmy had been growing very fast over the past 6-12 months.  Jimmy’s mother wasn’t sure if she should be concerned or if it was just one of those childhood “growth spurts.”  She took Jimmy to see his pediatrician and the physical examination showed that Jimmy had, in fact picked up his rate of growth and was now well above the 95% for height.   Since Jimmy’s mother and father are both tall (mother 68 inches tall and father 74 inches tall), the pediatrician reassured the parents that Jimmy’s growth spurt was of no concern.

Jimmy’s mother was not completely reassured by the pediatrician particularly since she had also noted some personality changes along with the increased growth, most notably much more aggressive behaviors.  The friend listened to Jimmy’s mother and suggested that, perhaps, a second opinion was in order, if only to allay the mother’s anxiety over the situation.

Is Jimmy’s mother’s anxiety justified?

The question is whether so-called “growth spurts” really do occur during childhood as part of the normal growth process.  The answer is that sustained major changes in growth velocity during childhood are not normal.  If one studies growth in children with careful height measurements every month for many years, there are definite month-to-month differences in rates, but they tend to average out over time.  One very important principle of growth is that children tend to follow whatever growth channel they are at all through childhood.  This means that a child who is at the 10% for height at age 2 years, is very likely to remain at that percentile throughout childhood, assuming the child is generally healthy; serious illnesses or other medical conditions can affect the growth rate.  There are  2 exceptions to the rule; the first is growth from birth until about age 18 months, and the other is growth during puberty.

A child who starts out in a higher height channel than the one he is genetically programmed to follow, typically follows the higher channel for about 6 months and then gradually falls and falls until about age 18 months when he  reaches the channel he will follow faithfully thereafter (by thereafter, I mean until the onset of puberty).  This growth pattern is called deceleration.  It can give doctors gray hair since the deceleration could be a normal physiologic growth pattern or one that indicates some medical disorder.

In a newborn who is programmed to follow a higher growth channel than the one at birth, the growth pattern is called acceleration; the infant picks up his linear growth rate almost immediately after birth  and attains the channel he will follow thereafter, by about one year of age.

Puberty is the second exception to the general rule that children stick to growth channels almost no matter what .  All bets are off as to the growth rate during puberty.  Typically, girls show pubertal growth acceleration about the time they start breast development (on average age 10.5-11 years) and are slowing down by the time they have their first menstrual period, about 2 years after starting breast development.  Boys typically show pubertal changes at about age 11.5-12 years but do not show much in the way of growth acceleration until 12.5-13 years and don’t slow down until about age 15-16 years.

Back to Jimmy

So, when Jimmy’s mother took him to see a pediatric endocrinologist (I am partial to pediatric endocrinologists but I might have recommended that Jimmy’s mother first make another appointment with the pediatrician to address  her continuing concerns).  After the pediatric endocrinologist obtained the medical history, which included old medical records with serial height measurements, he formulated a preliminary differential diagnosis.  Review of the old records showed clearly a rather impressive acceleration in linear growth as well as weight beginning about 18 months earlier.

Next step

So, how would the pediatric endocrinologist think about things so far?  Even before the physical examination, it is likely the “wheels are turning” and the physician is formulating a preliminary differential diagnosis that will help guide the physical examination.  Assuming the medical history is accurate (rapid growth, personality change), the differential diagnosis is not very difficult; very few conditions are associated with the historical information.  Rapid growth in children could be cause by improvement in a medical condition that was inhibiting growth such as celiac disease.  The history does not suggest such a possibility.  Another cause of rapid growth could be excess growth hormone.  Since there was no history of growth hormone injections or administration of any other drugs, the likely causes of growth hormone excess would be central nervous system tumors, particularly pituitary adenomas.  This is a rare cause of accelerated growth in children, but I have seen a few cases so it does occur.  Much more likely would be an excess of either male or female sex hormones.  The history of aggressive behavior would certainly fit with an excess of make sex hormones.  What disorders might cause excessive male or female sex hormones?  The possibilities include central (hypothalamic-pituitary origin) precocious puberty for whatever reason (e.g, a variety of central nervous system diseases, idiopathic central precocious puberty), or pubertal changes that are the result of non-central system conditions.  Examples would include a human chorionic gonadotropin-secreting tumor, possibly of the testis, autonomous overfunction of the testes (so-called “testitoxicosis) leading to precocious puberty, or the most likely possibility, a condition affecting the adrenal glands, either congenital adrenal hyperplasia or an adrenal tumor (adenoma or carcinoma).  That’s about it in terms of the possibilities.  The physical examination would help a great deal in “narrowing the field.”

The physical examination

The patient was quite cooperative.  Vital signs were normal.  His height and weight were greater than the 95% for age.  The general examination was normal for age except for the presence of mild facial acne and genital abnormalities.  The penis was clearly pubertal in size and the patient had pubic hair.  The testes were normally descended and were pre-pubertal in size.  Underarm sweating was present.

What do the physical examination findings mean?

The physical examination was clearly abnormal for a 7 year old boy; in a male, the earliest pubertal change is normally testicular enlargement at about age 11.5-12 years along with some underarm sweating and perhaps a bit of pubic hair.  By definition, pubertal changes in males are considered precocious if they begin before age 9-9.5 years of age.  So, Jimmy has precocious puberty and this is clearly the reason for the rapid growth.  Now the question is what has caused the precocious puberty?  There are many different ways of classifying precocious puberty.  I like to separate precocious puberty into 2 broad categories, true puberty and pseudo-puberty. I use the term “true puberty” to mean pubertal changes that are the result of pituitary hormones, FSH and LH stimulating the gonads to produce male sex hormones, principally testosterone in males, and estrogen in females.  If the puberty is caused byFSH and LH-like hormones (principally human chorionic gonadotropin or HCG)  that may or may not be coming from the pituitaryI would  still call it true puberty.  The other category, “pseudo-puberty”, refers to pubertal changes that are not caused by pituitary or pituitary-like hormone messengers to the gonads.  The pseudo-puberty could be either isosexual or heterosexual; in isosexual puberty the sexual changes are what one would expect given the person’s chromosomal make-up (i.e., breast development in a female) while in heterosexual puberty the sexual changes would be just the opposite (i.e.,breast enlargement in a male).  So, in Jimmy we havearly puberty which is clearly isosexual but pseudo-puberty.  We know that because the testes are pre-pubertal in size; if it had been true puberty, the testres would have been enlarged from pituitary or pituitary-like hormones with production of male sex hormones in the testes.

Where do we go from here?

So, Jimmy has precious puberty which is not the result of male sex hormones being produced by the testes.  In this situation the most likely possibility is that the male sex hormones are coming from one or both adrenal glands (it is pretty unlikely that Jimmy is taking anabolic steroids to improve his athletic performance).  The differential diagnosis is either an adrenal tumor, adenoma or carcinoma, both quite rare in children, or a disorder called congenital adrenal hyperplasia or CAH.  CAH is a group of genetic disorders that are the result of various blocks in the pathway to synthesis of the adrenal gland hormone cortisol,  and in some instances, also a block in the salt-retaining hormone, aldosterone.  There are 5 known different types of CAH, each caused by a deficiency in a specific enzyme necessary for cortisol synthesis.  The blocks can be complete or partial.  Each of the 5 types of CAH are quite distinct in the way they present.  The most common form of CAH is deficiency of an enzyme called 21-hydroxylase.  Patients with 21-hydroxlase deficiciency CAH produce large quantities of male sex hormones.  At any rate it is quite easy to diagnose the various forms of CAH and pin down the specific enzyme deficiency.  In fact, most states in the U.S., screen newborns for the 21-hydroxlase deficiency form of CAH.

So, armed with some knowledge about the various forms of precocious puberty, a medical history and a physical examination, the pediatric endocrinologist is ready to order a few laboratory studies.  I would be inclined to order the following tests: an X-ray of the left hand to determine Jimmy’s “bone age,” to get some idea of how advanced his bone growth centers were; both male and female sex hormones cause maturation of the bone growth centers which can greatly affect linear growth potential.  If for example, Jimmy’s bone age has already advanced to 12 or 13 years of age, his growth potential is much more limited than if his bone age were appropriate for age.  Thus, even though Jimmy might be tall for his age now, he might end up quite short.  I would order some hormone levels- testosterone, 17-hydroxyprogesterone, dehydroepiandrosterone (DHEA), and renin.  The results of these 3 tests would go a long way in helping the pediatric endocrinologist determine the exact cause of the precocious puberty.  One could order many more tests including MRIs and CAT scans (to look for tumors), but I would start simple and do a stage evaluation.

What did the laboratory studies show and what do the results mean?

The bone age was read by the radiologist as being 12 years.  This means that the radiologist looked at Jimmy’s left hand X-ray (by convention bone ages are always of the left hand) and compared the appearance of the bone growth centers to those in an atlas and found that Jimmy’s hand bone growth centers looked most like the 12 year old male standard photo in the atlas ,hich is just a series of hand X-rays taken at different ages (obviously, there are separate male and female atlas sections).  So, Jimmy has quite an advanced bone age and it has to be the result of excessive male sex hormones.  The blood studies showed elevated levels for the testosterone and the 17-hydroxprogesterone but not the other analytes.  This was actually all the pediatric endocrinologist needed to make a more-or-less definitive diagnosis.

The pre-hormone 17-hydroxprogesterone, is the product in the synthetic pathway for cortisol just before the step catalyzed by the enzyme 21-hydroxylase.  If the level of 21-hydroxylase is low, cortisol synthesis will slow up (or be completely blocked if there is no 21-hydroxlase present) and the pre-hormones before the block will pile up- just like water backing up where a dam is built.  As it turns out, the pre-hormones before the 17-hydroxprogesterone can follow an alterntive pathway and it shouldn’t surprise you that  they march down the pathway to make male sex hormones, testosterone and androstendione.   The DHEA was ordered because another form of CAH that can cause precocious puberty is the result of  a “back-up” at the step just after formation of DHEA.  One other form of  CAH causes precocious puberty, but in that disorder, patients usually have very high blood pressures, something Jimmy did not have.  Finally, the renin was ordered to see if along with a deficiency in cortisol synthesis, there was also a deficiency in the salt-retaining hormone, aldosterone which is found in about 70% of children with 21-hydroxylase deficiency.

So, Jimmy likely has CAH due to a deficiency in the enzyme, 21-hydroxylase which results in an excess of 17-hydroxprogesterone which in turn results in excess synthesis of male sex hormones.

Next step: treatment and confirmation of the diagnosis

The next step is to treat the patient with a glucocorticoid hormone such as cortisol which basically turns off the oversynthesis of male sex hormones.  If we obtain a blood specimen for 17-hydroxyprogesterone and testosterone several weeks after starting the treatment with cortisol, we can definitively confirm the diagnois of 21-hydroxlase deficiency CAH if the  17-hydroxprogesterone and testosterone levels have decreased.  This also means that the reason for the elevated testosterone cannot be an adrenal tumor since the tumor production of male sex hormones is not affected by treatment with cortisol- just think of how much money we saved by holding off on the MRI and CAT scan tests!

Lessons learned?

So, now we know what made Jimmy grow so fast and we know how to treat it.  Our goal is to treat him with enough cortisol to completely block  the excessive adrenal hormone production but not so much as to lead to side effects from overtreatment (this would be called Cushing’s syndrome).  With some luck, we have caught the problem early enough that it will not markedly decrease Jimmy’s growth potential.  One potential problem is that when the bone age gets to a pubertal level, that may trigger onset of true puberty.  But, we now have drugs that can slow that process if necessary.  The main lesson to be learned from this case is that physicians should not be so quick to assume that a particular physical finding or symptom in a patient is ok just because it may “run in the family.”  Tall stature in a child would not be surprising if the parents were tall but tall stature that does not “follow the rules” should raise red flags.  Similarly, just because a parent has a history of migraine heaaches does not mean that the child’s severe headaches are also migraines.

FYI: An Article About Growth Hormone For Short Children

My wife sent me an e-mail this morning to let me know about an article published on-line at Salon.com entitled “Growth Hormone For Kids,” written by Rahul Parikh. The article addressed the question of whether short children who have no specific medical condition to explain their short stature should be treated with growth hormone injections. So, the question is whether children who have so-called “idiopathic short stature” should be treated with growth hormone with the intention of making them taller adults than they would otherwise be without the injections. The author comes down on the side of not treating such patients but the issue is actually rather complex and, in my opinion, there are no easy answers.

In 2003, the U.S. Food and Drug Administration (FDA) approved the use of growth hormone injections in idiopathic short stature with several caveats: the child must be short and growing at a rate that would not likely result in their achieving an adult height in the normal range, defined as 59 inches for a girl and 63 inches for a boy. In addition, the bone growth centers must be still open and the child must not have some medical condition that would explain the short stature.

I have no idea how many children in the U.S. have been and are currently receiving growth hormone injections for idiopathic short stature. I do not know of any insurers that cover the treatment, which can be quite expensive- as much as $50,000 or more per year. There is no consensus among pediatric endocrinologists (the docs who mostly deal with growth hormone treatment for short stature) whether short stature per se is a disease worthy of treatment with growth hormone or merely a cosmetic condition for which use of growth hormone should not be considered medically necessary (“medically necessary” is a term I discussed in one of my earlier entries and I would refer you to that in case you have forgotten what I wrote- actually, I can’t even remember what I wrote). Anyway, the article is interesting and the accompanying letters to the editor are particularly interesting. I even wrote a letter, which didn’t make the editor’s list of “the best 3 letters,” but you can find it on page 3 or 4 of the letters.

What Is “Medical Necessity” And What Does It Have To Do With Growth Hormone Treatment?

Recently I received a draft document on growth hormone treatment policies from a leading health insurance company. I was asked to review the document and to offer comments. The document, which was 26 pages long, detailed the company’s proposed changes in the criteria they will use to approve or deny requests by physicians that the insurer pay for use of synthetic human growth hormone. At present, at least 8 pharmaceutical companies manufacture and market human growth hormone (I have no idea how many companies sell bovine and other animal growth hormones- growth hormone is species specific in terms of having biological action). Also, at present, there are at least 10 specific medical diagnoses for which use of growth hormone therapy is FDA-approved.

Why does the insurer want a new set of policies on the use of human growth hormone?

If I had to bet or die, I’d say the insurer has noticed an alarming increase in requests for growth hormone treatment over the past few years and given the costs for growth hormone, which can be up to $100,000 per year per patient, they just did the math and found the results frightening. The proposed new policies are designed to “slow the bleeding.” And who can blame the company for trying to keep costs down- increased costs mean lower profits for them and/or increased costs for insurees? The question I want to address here is whether it is possible for an insurer to maintain quality of service (i.e, pay for services that are needed for the insuree’s health and well-being), yet keep costs from going up and up and up? Here, we’ll focus on human growth hormone, but the question is really a general one that our society will have to come to grips with sooner rather than later.

What is “medical necessity?”

Most people would agree that medical insurers should not “cover” (i.e., pay for) treatments that are not medically necessary. The problem is deciding exactly what is a medically necessary treatment. In the situation under consideration here, the insurer has defined medically necessary as “procedures, treatments, supplies, devices, equipment, facilities or drugs that a medical practitioner, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury or disease or its symptoms that are: in accordance with generally accepted standards of medical practice; and clinically appropriate in terms of type, frequency, extent, site and duration and considered effective for the patient’s illness, injury or disease; and not primarily for the convenience of the patient, physician or other health care provider; and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient’s illness, injury or disease.” Furthermore, the insurer defines “generally accepted standards of medical practice” as “standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, national physician specialty society recommendations and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors.”

Is treatment with growth hormone medically necessary?

In 1984, biosynthetic growth hormone was FDA-approved for use in children with growth hormone deficiency. The drug was offered by a single pharmaceutical company and it was expensive, but there was no real debate whether the drug was medically necessary in “classic” cases,those patients who were exceedingly short and in whom growth hormone deficiency was well documented. The general principle here was that in treating a patient with growth hormone deficiency, one was correcting a pathological situation with serious consequences if left untreated (even beyond the short stature). That was easy. But next came the hard part- a series of conditions were shown to be “growth hormone responsive” even though patients were not growth hormone deficient. That is, patients with certain clinical disorders associated with short stature who were clearly not growth hormone deficient, showed increased liner growth with growth hormone treatment. Examples include patients with Turner’s syndrome, Prader-Willi syndrome, mild renal disease, intrauterine growth retardation, and adults with growth hormone deficiency. One by one, growth hormone was FDA-approved for these and other disorders. Finally, in 2003, growth hormone was approved for children with “idiopathic short stature,” that is, children who are short but have no specific medical condition to explain their short stature. So, in essence, growth hormone became FDA-approved for children with short stature whatever the reason as long as they are likely not to achieve an adult height in the normal range (nominally defined as 59 inches tall in females and 63 inches tall in males and still have open bone growth centers.

The big question

So, it is not surprising that if a person takes enough growth hormone and for long enough while their bone growth centers are open, they will end up taller. We have known this for many years from patients with pituitary tumors that produce growth hormone (in adults the condition is called acromegaly, and in children it is called pituitary gigantism). So is it medically necessary to treat patients with short stature from whatever diagnosis in order to help them achieve an adult height in the normal range? And, if reaching an adult height of 63 inches is good, why not 73 inches? There is a widespread belief that “taller is better,” and considerable data support that notion in terms of earning power, social acceptance, etc. This is the crux of the problem. Is it medically necessary to make all potentially short adults taller, or is it really a cosmetic therapy, similar to cosmetic rhinoplasty, breast reduction/augmentation, and botox for wrinkles?

There may be moral and ethical questions regarding cosmetic therapies but few argue against the right of individuals to receive these types of therapies, assuming they have been proven to be safe. The question is if an insurer (i.e., all insurees) should be forced to pay for such therapies. It isn’t so easy to come up with answers. For example, is psychological trauma in a teenage girl with a misshapen nose a medical condition that fulfills the definition of medical necessity as described above? Another example is gynecomastia in a teenage boy. Is surgery to correct this abnormality merely cosmetic, even if the situation is psychologically devastating, or is it medically necessary?

Back to growth hormone

I got a bit off track in an effort to explain the problem with using “medical necessity” to determine the appropriateness of growth hormone treatment in some patients with short stature. With respect to growth hormone, the question given the enormous expense of the drug is not whether it is efficacious (i.e., increases height), but rather, whether it is medically necessary. This is really a question of rationing medical care, something that none of us like to talk about but what is surely coming, given the rapidly rising costs of medical care. It is not surprising that insurers are looking first at their most expensive services to determine if some cost savings can be achieved. These are issues that none of us can hide from. In the long run, patients will be better served if medical practitioners and insurers can sit down and discuss how best to manage these complicated situations, given that medical costs are going up and up and someday soon we will need to make painful choices about which medical therapies are clearly medically necessary and which are a luxury.  In my opinion, having an insurer ask pediatric endocrinologists what they think about such issues  with respect to growth hormone prescribing is a step in the right direction.  Of course, one important question that I didn’t discuss at all is why growth hormone costs so much- I’ll leave that question for the economists to debate.

More About Big Dogs and Little Dogs

Probably from all the excitement about the report yesterday in the journal Science explaining why little dogs are little and big dogs are big, I forgot to mention a couple of things in my posting about the report. First, do you know why pigmies are short? It could be that they have the IGF-1 suppressor gene just like the little dogs.  Actually, they don’t; in the pigmies, the “problem” (I suspect the pigmies don’t consider their short stature a problem, just the normal state of affairs) is failure to respond to the IGF-1/IGFBP3 complex- they just don’t generate whatever growth factors are normally stimulated by the IGF-1/IGF-1BP3.  Just another example of what I mentioned yesterday- in nature, generally whatever can go wrong will do so sometimes.  Of course, we should be thankful that most of the time, things work just fine.

One other thing- treating people (or dogs) with IGF-1. I forgot to mention that IGF-1 must be injected, it’s very expensive,  and it causes hypoglycemia (low blood glucose levels).  Thus, treatment with IGF-1 has medical and financial risks.  The reason it causes hypoglycemia is that the structure of IGF-1 is very similar to the precursor molecule to insulin, proinsulin.  Thus, the IGF-1 acts like insulin in some ways.  I think that’s pretty interesting.

Why Are Scottie Dogs So Small and Great Danes So Big?

There is an interesting piece in the New York Times today ( Friday April 6, 2007, page A13) entitled “Difference Between Mutts and Jeffs? A Gene,” written by Donald G. McNeil, Jr. Before I get to the article, I need to tell you something about how children grow. There are many genetic and environmental factors that influence rate of growth and ultimate adult stature (just like there are many genetic and environmental factors that contribute to body weight).

For the moment, let’s just focus on some known hormonal influences on growth. Hormones are substances, usually polypeptides or proteins, that send messages to cells telling them what to do. We know that a hormone called growth hormone-releasing hormone (GHRH) which is produced in the hypothalamus (part of the brain), stimulates the pituitary gland (also in the brain) to produce and secrete another hormone called growth hormone (GH). GH circulates bound to a protein called GH-binding protein GHBP. The GH/GHBP complex binds to the liver where it stimulates production and secretion of another hormone called insulin growth factor 1 (IGF-1). IGF-1 circulates in the blood bound to another protein, IGFBP-3. Finally, the IGF-1/IGFBP-3 complex binds to tissues throughout the body, particularly muscle and bone, to promote growth. Sounds complicated? I suppose, but it’s a pretty slick system. We now know that in complex systems just about everything that could go wrong will. That is true for the growth hormone system; abnormalities and genetic variations have been described for each of the steps leading to the final expression of growth hormone secretion which is growth.

Growth hormone deficiency is one of the known causes for poor linerar growth. There are many different reasons for growth hormone deficiency (e.g., an absent pituitary gland, a pituitary gland damaged by radiation for treatment of a brain tumor, a genetic defect in formation of IGF-1). Thus GH deficiency is really a term used to describe a large number of possible abnormalities in the hormonal chain from the brain GHRH to the binding of the IGF-1/IGFBP3 complex in the tissues targeted for growth.

Back to the news report

So, the news article published today summarizes a study published today in the journal Science. According to the news report, the study which was led by Elaine A. Ostrander from the National Human Genome Research Institute, analyzed more than 3000 purebreds from 143 breeds. The researchers found that virtually all small dog breeds had a tiny bit of DNA that suppressed the “insulin-like growth factor 1″ gene; this suppressor gene was not present in large dog breeds. From what we discussed above, you can predict exactly what such a suppressor gene would do to linear growth and why: growth is slowed in the small dog breeds because they can’t generate nearly as much IGF-1 as the large dog breeds. So, in effect, small dog breeds have growth hormone deficiency, partial or complete depending on the extent of the IGF-1 suppression.

What are the clinical implications?

In humans, IGF-1 has been synthesized through recombinant DNA techniques and is being used in certain clinical situations. I’m not certain, but I think IGF-1s are species-specific (as are pituitary growth hormones). If this is true one probably couldn’t make a juvenile Scottie dog into a Great Dane-sized Scottie dog adult by giving human IGF-I injections. But who’s going to stop some enterprising scientist from trying it or from making a variety of small dog IGF-1s? Of course, one could also argue that we should insert the suppressor DNA into the genome of lovable large dogs to make them small and lovable? Oh the possibilites are just endless? Isn’t genetics interesting?

Anyway, in future entries, I promise to come back to growth hormone and growth in children. This news report was just too interesting to ignore.